News Release

Learn about the HIPGEN Phase III clinical trial at the Virtual WCO-IOF-ESCEO 2021

The year’s key annual congress in the bone and musculoskeletal field will present a satellite symposium dedicated to the HIPGEN clinical trial, a multinational study which aims to improve patient mobility after hip fracture arthroplasty

Meeting Announcement

International Osteoporosis Foundation

August 23, 2021 - Nyon, Switzerland

The Hipgen Trial - Cell Therapy for Improving Patient Mobility after Hip Fracture Arthroplasty’, is among the many topical symposia scheduled at the upcoming virtual World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2021).

HIPGEN is a Phase III, multicenter, randomized, double-blind, placebo-controlled trial, designed to determine the efficacy, safety and tolerability of intramuscular injections of allogeneic placenta-expanded adherent stromal (PLX-PAD) cells for improved recovery following arthroplasty for hip fracture. The HIPGEN study has received funding from the European Union’s Horizon 2020 research and innovation programme (grant agreement No 779293) and includes a network of 10 partners from eight countries, including the International Osteoporosis Foundation (IOF) as a communications partner. 

Professor Cyrus Cooper, President of IOF, stated:

“Of all osteoporosis-related fractures, hip fractures cause the most morbidity and mortality in older adults. It is of vital importance that the research community develops new strategies to improve the recovery and quality of life of older adults who undergo surgery after sustaining these severe injuries. As the largest NGO in the musculoskeletal field representing patient societies and the medical community, IOF is delighted to host a satellite symposium devoted to HIPGEN at its annual global Congress. It is a unique opportunity to share insights about the ongoing trial with orthopaedists, rehabilitation specialists and other musculoskeletal disease experts from around the world.” 

The Satellite Symposium entitled ‘The HIPGEN Trial - Cell Therapy For Improving Patient Mobility After Hip Fracture Arthroplasty’ is presented courtesy of Pluristem Therapeutics, the HIPGEN consortium partner responsible for the allogeneic PLX-PAD cell development. The Symposium will be held in a live virtual format on August 27th, 2021 (08:00-09:00 CET). Congress registrants may attend the live presentation or later view the recording on demand for three months after the Congress. 

The Symposium will be chaired by trial coordinator Professor Tobias Winkler, Charité Universitätsmedizin Berlin, Germany, and will feature the following lectures and presenters: 

  • Modern hip fracture surgery – What makes the Difference, Prof. Matthew Costa, University of Oxford
  • The HIPGEN Project – From early Data to Phase III, Prof. Tobias Winkler, Charité – Universitaetsmedizin Berlin
  • PLX Cells – A Portfolio for Allogeneic Regenerative Cell Therapy, Dr. Nitsan Halevy, Pluristem Therapeutics
  • Mechanism of Action - What can in vitro Studies contribute to Clinical MoA, speaker Prof. Ornella Parolini, Fondazione Poliambulanza and Università Cattolica del Sacro Cuore

Prof. Tobias Winkler, Charité - Universitaetsmedizin Berlin stated:

“The presented HIPGEN project is the first phase III trial bringing an Advanced Therapeutic Medicinal Product candidate to patients with hip fracture. We intend to potentially improve patient mobility and combat immobility with all its associated problems by strengthening the periarticular hip musculature with the help of cell therapy.”

The HIPGEN symposium is one of seven satellite and 24 non-sponsored symposia which will be held during the virtual Congress, which will include a wide range of sessions including plenary lectures, Meet-the-Expert sessions, topical symposia and oral presentations. 


About the World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO)
Held jointly by IOF and ESCEO, the WCO-IOF-ESCEO annual congress is the world’s largest forum for the presentation of clinical research and new advances in the prevention and management of musculoskeletal disorders, including sarcopenia and frailty. WCO-IOF-ESCEO 2021 will be held as a virtual congress from August 26 to 28, 2021, with access on demand for registrants up to three months following the congress. For complete information visit  #OsteoCongress

About IOF
The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as 268 patient, medical and research societies, work together to make fracture prevention and healthy mobility a worldwide heath care priority.  @iofbonehealth

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception.   


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.